The 14 linked references in paper I. Baranova A., E. Kondrat'eva I., S. Krasovskiy A., И. Баранова А., Е. Кондратьева И., С. Красовский А. (2017) “Остеопороз при муковисцидозе: меры профилактики и терапевтические возможности // Osteoporosis in cystic fibrosis patients: prevention and therapeutic opportunities” / spz:neicon:pulmonology:y:2017:i:4:p:537-545

  1. Каширская Н.Ю., Красовский С.А., Черняк А.В. и др. Динамика продолжительности жизни больных муковисцидозом, проживающих в Москве, и ее связь с получаемой терапией: ретроспективный анализ за 1993–2013 гг. Вопросы современной педиатрии. 2015; 14 (4): 503–508. DOI: 10.15690/vsp.v14.i4.1390.
  2. EFSA Panel on Dietetic Products Nutrition and Allergies. Scientific opinion on dietary reference values for calcium. EFSA J. 2015; 13 (5): 4101e83. DOI: 10.2903/j.efsa.2015. 41015..
  3. Tangpricha V., Kelly A., Stephenson A. et al. An update on the screening, diagnosis, management, and treatment of vitamin d deficiency in individuals with cystic fibrosis: evidence-based recommendations from the cystic fibrosis foundation from the Cystic Fibrosis Foundation.J. Clin. Endocrinol. Metab. 2012; 97 (4): 1082–1093. DOI: 10.1210/JC.2011-3050.
  4. Conwell L.S., Chang A.B. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst. Rev. 2014; (3): CD002010. DOI: 10.1002/14651858.CD002010.pub4.
  5. Sermet-Gaudelus I., Bianchi M.L., Garabédian M. et al. European cystic fibrosis bone mineralisation guidelines. J. Cyst. Fibros. 2011; 10 (Suppl. 2): S16S23. DOI: 10.1016/ S1569-1993(11)60004-0.
  6. Lekamwasam S., Adachi J.D., Agnusdei D. et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Osteoporos Int.2012; 23 (9): 2257–2276. DOI: 10.1007/s00198-012-1958-1.
  7. Лесняк О.М., Баранова И.А., Торопцова Н.В. Клинические рекомендации: Диагностика, профилактика и лечение глюкокортикоидного остеопороза у мужчин и женщин 18 лет и старше. Ярославль: Литера; 2014.
  8. Cosman F., de Beur S.J., LeBoff M.S. et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int.2014; 25 (10): 2359–2381. DOI: 10.1007/ s00198-014-2794-2.
  9. Watts N.B., Adler R.A., Bilezikian J.P. et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012; 97 (6): 1802–1822. DOI: 10.1210/ jc.2011-3045.
  10. Aris R.M., Merkel P.A., Bachrach L.K. et al. Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. Metab. 2005; 90 (3): 1888–1896. DOI: 10.1210/jc.2004-1629.
  11. Ward L.M., Konji V.N., Ma J. The management of osteoporosis in children.Osteoporos Int.2016; 27 (7): 2147–2179. DOI: 10.1007/s00198-016-3515-9.
  12. Whyte M.P., McAlister W.H., Novack D.V. et al. Bisphosphonate-induced osteopetrosis: novel bone modelling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases.J. Bone Miner. Res. 2008; 23 (10): 1698–1707. DOI: 10.1359/jbmr.080511.
  13. Ward L., Tricco A.C., Phuong P. et al. Biphosphonate therapy for children and adolescents with secondary osteoporosis.Cochrane Database Syst. Rev.2007; (4): CD005324. DOI: 10.1002/14651858.CD005324.pub2.
  14. Siwamogsatham O., Stephens K., Tangpricha V. Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series. Case Rep. Endocrinol. 2014; 2014: 893589. DOI: 10.1155/2014/893589. Поступила 26.12.16